Page last updated: 2024-10-22

altretamine and Recrudescence

altretamine has been researched along with Recrudescence in 3 studies

Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.

Research Excerpts

ExcerptRelevanceReference
"A number of active agents in ovarian cancer (platinum, paclitaxel, topotecan, liposomal doxorubicin, docetaxel, gemcitabine, and etoposide) will be reviewed in the context of what is known about cumulative toxicity, potential adverse effects on patients' quality of life, and evidence addressing the potential benefits of longer-term treatment."2.42Recurrent ovarian cancer: how important is it to treat to disease progression? ( Herzog, TJ, 2004)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (66.67)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Herzog, TJ1
Edelman, DZ1
Anteby, SO1
Peretz, T1
Ozols, RF1

Reviews

3 reviews available for altretamine and Recrudescence

ArticleYear
Recurrent ovarian cancer: how important is it to treat to disease progression?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-15, Volume: 10, Issue:22

    Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cis

2004
[Chemotherapy for recurrent or advanced persistent epithelial ovarian cancer].
    Harefuah, 1996, Volume: 131, Issue:1-2

    Topics: Altretamine; Antineoplastic Agents; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Ovarian Neopla

1996
Ovarian cancer: new clinical approaches.
    Cancer treatment reviews, 1991, Volume: 18 Suppl A

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ovarian Neoplasms; Recu

1991